Αγομελατίνη (Greek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Αγομελατίνη" in Greek language version.

refsWebsite

Global rank Greek rank

18nih.gov

4^th place

17doi.org

2^nd place

3^rd place

8web.archive.org

1^st place

6europa.eu

68^th place

24^th place

3books.google.com

3^rd place

6^th place

2archive.org

6^th place

5^th place

1tga.gov.au

3,984^th place

2,133^rd place

1medicines.org.uk

3,823^rd place

2,141^st place

1docguide.com

low place

1servier.com

low place

1worldcat.org

5^th place

8^th place

1servier.co.uk

low place

1wikiwix.com

194^th place

1,053^rd place

1clinicaltrials.gov

5,225^th place

7,320^th place

1scripintelligence.com

low place

archive.org

«The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways». The Journal of Pharmacology and Experimental Therapeutics 306 (3): 954–64. September 2003. doi:10.1124/jpet.103.051797. PMID 12750432. https://archive.org/details/sim_journal-of-pharmacology-and-experimental-therapeutics_2003-09_306_3/page/954.
«The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways». The Journal of Pharmacology and Experimental Therapeutics 306 (3): 954–64. September 2003. doi:10.1124/jpet.103.051797. PMID 12750432. https://archive.org/details/sim_journal-of-pharmacology-and-experimental-therapeutics_2003-09_306_3/page/954.

books.google.com

Australian Medicines Handbook 2013. Adelaide: The Australian Medicines Handbook Unit Trust. 2013. ISBN 9780980579093.
Joint Formulary Committee and Royal Pharmaceutical Society of Great Britain (2013). British National Formulary (BNF) 65. London, UK: Pharmaceutical Press. σελ. 253. ISBN 978-0857110848.
The Maudsley prescribing guidelines in psychiatry. West Sussex: Wiley-Blackwell. 2012. ISBN 978-0-470-97948-8.

clinicaltrials.gov

«Clinical trials for agomelatine». ClinicalTrials.gov. National Institutes of Health. Αρχειοθετήθηκε από το πρωτότυπο στις 4 Οκτωβρίου 2011. Ανακτήθηκε στις 6 Ιουλίου 2009.

docguide.com

dgnews.docguide.com

«Agomelatine Effective for Children, Adolescents With Depression». dgnews.docguide.com (στα Αγγλικά). Ανακτήθηκε στις 21 Σεπτεμβρίου 2020.

doi.org

dx.doi.org

«Agomelatine versus other antidepressive agents for major depression». The Cochrane Database of Systematic Reviews (12): CD008851. December 2013. doi:10.1002/14651858.CD008851.pub2. PMID 24343836.
«Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies». BMJ 348: g1888. March 2014. doi:10.1136/bmj.g1888. PMID 24647162.
«Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis» (στα αγγλικά). Lancet 391 (10128): 1357–1366. April 2018. doi:10.1016/S0140-6736(17)32802-7. PMID 29477251.
Norman, TR; Olver, JS (13 February 2019). «Agomelatine for depression: expanding the horizons?». Expert Opinion on Pharmacotherapy 20 (6): 647–656. doi:10.1080/14656566.2019.1574747. PMID 30759026.
«Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies». BMJ 348: g1888. March 2014. doi:10.1136/bmj.g1888. PMID 24647162.
«Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine». International Clinical Psychopharmacology 22 (5): 283–91. September 2007. doi:10.1097/YIC.0b013e3280c56b13. PMID 17690597.
«Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal». The International Journal of Neuropsychopharmacology 15 (3): 417–28. April 2012. doi:10.1017/S1461145711001301. PMID 21859514.
«Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials». The British Journal of Psychiatry 203 (3): 179–87. September 2013. doi:10.1192/bjp.bp.112.120196. PMID 23999482.
«A benefit-risk assessment of agomelatine in the treatment of major depression». Drug Safety 34 (9): 709–31. September 2011. doi:10.2165/11593960-000000000-00000. PMID 21830835.
«Agomelatine versus other antidepressive agents for major depression». The Cochrane Database of Systematic Reviews (12): CD008851. December 2013. doi:10.1002/14651858.CD008851.pub2. PMID 24343836.
Quera Salva, Maria-Antonia; Vanier, Bernard; Laredo, Judith; Hartley, Sarah; Chapotot, Florian; Moulin, Catherine; Lofaso, Frédéric; Guilleminault, Christian (2007-05-04). «Major depressive disorder, sleep EEG and agomelatine: an open-label study». The International Journal of Neuropsychopharmacology 10 (5): 691–696. doi:10.1017/S1461145707007754. ISSN 1461-1457. PMID 17477886.
«Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness». CNS Drugs 24 (6): 479–99. June 2010. doi:10.2165/11534420-000000000-00000. PMID 20192279.
«Depression: chronophysiology and chronotherapy». Biological Rhythm Research 45: 77–91. June 2013. doi:10.1080/09291016.2013.797657.
«The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways». The Journal of Pharmacology and Experimental Therapeutics 306 (3): 954–64. September 2003. doi:10.1124/jpet.103.051797. PMID 12750432. https://archive.org/details/sim_journal-of-pharmacology-and-experimental-therapeutics_2003-09_306_3/page/954.
«Agomelatine, an innovative pharmacological response to unmet needs». Journal of Psychopharmacology 22 (7 Suppl): 4–8. September 2008. doi:10.1177/0269881108092593. PMID 18753276.
«The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways». The Journal of Pharmacology and Experimental Therapeutics 306 (3): 954–64. September 2003. doi:10.1124/jpet.103.051797. PMID 12750432. https://archive.org/details/sim_journal-of-pharmacology-and-experimental-therapeutics_2003-09_306_3/page/954.
«N-[2-(7-Methoxy-1-naphthyl)ethyl]acetamide, a potent melatonin analog». Acta Crystallogr. C 50 (6): 907–910. 1994. doi:10.1107/S0108270193012922.

europa.eu

ema.europa.eu

«Thymanax EPAR». European Medicines Agency (EMA). Ανακτήθηκε στις 14 Ιανουαρίου 2021.
«Valdoxan EPAR». European Medicines Agency (EMA). Ανακτήθηκε στις 14 Ιανουαρίου 2021.
«Product Information: Valdoxan, INN-agomelatine» (PDF). www.ema.europa.eu. European Medicines Agency. 13 Νοεμβρίου 2013. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 29 Οκτωβρίου 2014. Ανακτήθηκε στις 27 Φεβρουαρίου 2016.
«Summary of Product Characteristics» (PDF). European Medicine Agency. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 29 Οκτωβρίου 2014. Ανακτήθηκε στις 14 Οκτωβρίου 2013.
«CHMP Assessment Report for Valdoxan». European Medicines Agency. 20 November 2008. Αρχειοθετήθηκε από το πρωτότυπο στις 24 April 2011. https://web.archive.org/web/20110424023843/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf. Ανακτήθηκε στις 6 July 2009.

emea.europa.eu

«Questions and Answers on Recommendation for Refusal of Marketing Authorisation». European Medicines Agency. 18 November 2006. Αρχειοθετήθηκε από το πρωτότυπο στις 2020-03-02. https://web.archive.org/web/20200302212446/http://www.emea.europa.eu/humandocs/PDFs/EPAR/valdoxan/H-656-657-RQ%26A-en.pdf. Ανακτήθηκε στις 6 July 2009.

medicines.org.uk

«Valdoxan 25 mg film-coated tablets - Summary of Product Characteristics (SmPC)». (emc). 13 Ιουλίου 2020. Ανακτήθηκε στις 14 Ιανουαρίου 2021.

nih.gov

ncbi.nlm.nih.gov

«Agomelatine versus other antidepressive agents for major depression». The Cochrane Database of Systematic Reviews (12): CD008851. December 2013. doi:10.1002/14651858.CD008851.pub2. PMID 24343836.
«Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies». BMJ 348: g1888. March 2014. doi:10.1136/bmj.g1888. PMID 24647162.
«Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis» (στα αγγλικά). Lancet 391 (10128): 1357–1366. April 2018. doi:10.1016/S0140-6736(17)32802-7. PMID 29477251.
Norman, TR; Olver, JS (13 February 2019). «Agomelatine for depression: expanding the horizons?». Expert Opinion on Pharmacotherapy 20 (6): 647–656. doi:10.1080/14656566.2019.1574747. PMID 30759026.
«Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies». BMJ 348: g1888. March 2014. doi:10.1136/bmj.g1888. PMID 24647162.
«Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine». International Clinical Psychopharmacology 22 (5): 283–91. September 2007. doi:10.1097/YIC.0b013e3280c56b13. PMID 17690597.
«Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal». The International Journal of Neuropsychopharmacology 15 (3): 417–28. April 2012. doi:10.1017/S1461145711001301. PMID 21859514.
«Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials». The British Journal of Psychiatry 203 (3): 179–87. September 2013. doi:10.1192/bjp.bp.112.120196. PMID 23999482.
«A benefit-risk assessment of agomelatine in the treatment of major depression». Drug Safety 34 (9): 709–31. September 2011. doi:10.2165/11593960-000000000-00000. PMID 21830835.
«Agomelatine versus other antidepressive agents for major depression». The Cochrane Database of Systematic Reviews (12): CD008851. December 2013. doi:10.1002/14651858.CD008851.pub2. PMID 24343836.
Quera Salva, Maria-Antonia; Vanier, Bernard; Laredo, Judith; Hartley, Sarah; Chapotot, Florian; Moulin, Catherine; Lofaso, Frédéric; Guilleminault, Christian (2007-05-04). «Major depressive disorder, sleep EEG and agomelatine: an open-label study». The International Journal of Neuropsychopharmacology 10 (5): 691–696. doi:10.1017/S1461145707007754. ISSN 1461-1457. PMID 17477886.
«Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness». CNS Drugs 24 (6): 479–99. June 2010. doi:10.2165/11534420-000000000-00000. PMID 20192279.
«The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways». The Journal of Pharmacology and Experimental Therapeutics 306 (3): 954–64. September 2003. doi:10.1124/jpet.103.051797. PMID 12750432. https://archive.org/details/sim_journal-of-pharmacology-and-experimental-therapeutics_2003-09_306_3/page/954.
«Agomelatine, an innovative pharmacological response to unmet needs». Journal of Psychopharmacology 22 (7 Suppl): 4–8. September 2008. doi:10.1177/0269881108092593. PMID 18753276.
«The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways». The Journal of Pharmacology and Experimental Therapeutics 306 (3): 954–64. September 2003. doi:10.1124/jpet.103.051797. PMID 12750432. https://archive.org/details/sim_journal-of-pharmacology-and-experimental-therapeutics_2003-09_306_3/page/954.

pubmedcentral.nih.gov

«Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies». BMJ 348: g1888. March 2014. doi:10.1136/bmj.g1888. PMID 24647162.
«Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis» (στα αγγλικά). Lancet 391 (10128): 1357–1366. April 2018. doi:10.1016/S0140-6736(17)32802-7. PMID 29477251.
«Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies». BMJ 348: g1888. March 2014. doi:10.1136/bmj.g1888. PMID 24647162.

scripintelligence.com

Malone, Eleanor (25 Οκτωβρίου 2011). «Novartis drops future blockbuster agomelatine». Scrip Intelligence. Αρχειοθετήθηκε από το πρωτότυπο στις 11 Νοεμβρίου 2011.

servier.co.uk

Bentham, Clara (2006-03-29). «Servier and Novartis sign licensing agreement for agomelatine, a novel treatment for depression». Servier UK. Αρχειοθετήθηκε από το πρωτότυπο στις 16 April 2009. https://web.archive.org/web/20090416210513/http://www.servier.co.uk/news/news-details.asp?StoryID=76. Ανακτήθηκε στις 2009-05-15.

servier.com

«Information about Valdoxan for patients». Servier. Αρχειοθετήθηκε από το πρωτότυπο στις 10 Δεκεμβρίου 2012. Ανακτήθηκε στις 10 Δεκεμβρίου 2012.

tga.gov.au

ebs.tga.gov.au

«Valdoxan Product Information» (PDF). TGA eBusiness Services. Servier Laboratories Pty Ltd. 23 Σεπτεμβρίου 2013. Αρχειοθετήθηκε από το πρωτότυπο στις 24 Μαρτίου 2017. Ανακτήθηκε στις 14 Οκτωβρίου 2013.

web.archive.org

«Valdoxan Product Information» (PDF). TGA eBusiness Services. Servier Laboratories Pty Ltd. 23 Σεπτεμβρίου 2013. Αρχειοθετήθηκε από το πρωτότυπο στις 24 Μαρτίου 2017. Ανακτήθηκε στις 14 Οκτωβρίου 2013.
«Product Information: Valdoxan, INN-agomelatine» (PDF). www.ema.europa.eu. European Medicines Agency. 13 Νοεμβρίου 2013. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 29 Οκτωβρίου 2014. Ανακτήθηκε στις 27 Φεβρουαρίου 2016.
«Summary of Product Characteristics» (PDF). European Medicine Agency. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 29 Οκτωβρίου 2014. Ανακτήθηκε στις 14 Οκτωβρίου 2013.
«Information about Valdoxan for patients». Servier. Αρχειοθετήθηκε από το πρωτότυπο στις 10 Δεκεμβρίου 2012. Ανακτήθηκε στις 10 Δεκεμβρίου 2012.
«Questions and Answers on Recommendation for Refusal of Marketing Authorisation». European Medicines Agency. 18 November 2006. Αρχειοθετήθηκε από το πρωτότυπο στις 2020-03-02. https://web.archive.org/web/20200302212446/http://www.emea.europa.eu/humandocs/PDFs/EPAR/valdoxan/H-656-657-RQ%26A-en.pdf. Ανακτήθηκε στις 6 July 2009.
«CHMP Assessment Report for Valdoxan». European Medicines Agency. 20 November 2008. Αρχειοθετήθηκε από το πρωτότυπο στις 24 April 2011. https://web.archive.org/web/20110424023843/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf. Ανακτήθηκε στις 6 July 2009.
Bentham, Clara (2006-03-29). «Servier and Novartis sign licensing agreement for agomelatine, a novel treatment for depression». Servier UK. Αρχειοθετήθηκε από το πρωτότυπο στις 16 April 2009. https://web.archive.org/web/20090416210513/http://www.servier.co.uk/news/news-details.asp?StoryID=76. Ανακτήθηκε στις 2009-05-15.
Malone, Eleanor (25 Οκτωβρίου 2011). «Novartis drops future blockbuster agomelatine». Scrip Intelligence. Αρχειοθετήθηκε από το πρωτότυπο στις 11 Νοεμβρίου 2011.

wikiwix.com

archive.wikiwix.com

«Clinical trials for agomelatine». ClinicalTrials.gov. National Institutes of Health. Αρχειοθετήθηκε από το πρωτότυπο στις 4 Οκτωβρίου 2011. Ανακτήθηκε στις 6 Ιουλίου 2009.

worldcat.org

Quera Salva, Maria-Antonia; Vanier, Bernard; Laredo, Judith; Hartley, Sarah; Chapotot, Florian; Moulin, Catherine; Lofaso, Frédéric; Guilleminault, Christian (2007-05-04). «Major depressive disorder, sleep EEG and agomelatine: an open-label study». The International Journal of Neuropsychopharmacology 10 (5): 691–696. doi:10.1017/S1461145707007754. ISSN 1461-1457. PMID 17477886.